VALCONTIN

This brand name is authorized in Nigeria.

Active ingredients

The drug VALCONTIN contains one active pharmaceutical ingredient (API):

1	Valproic acid UNII 5VOM6GYJ0D - VALPROATE SODIUM
	Valproic acid is anti-convulsant. The most likely mode of action for valproate is potentiation of the inhibitory action of gamma amino butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA.
	Read more about Valproic acid

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-5954	Tablet	Valcontin 500 Tablet TAB 333 mg; 145 mg 10 x 10's (in Aluminum Strips)	Controlled Release Tablets of Sodium Valproate and Valproic Acid. White to off white, caplet-shaped, biconvex, plain film-coated tablet. Each tablet contains: Sodium Valproate BP 333 mg, Valproic acid USP 145 mg (Both together correspond to Sodium Valproate 500 mg in a Continus™ controlled-release system)	26/04/2023
A4-5955	Tablet	Valcontin 200 Tablet TAB 133.5 mg; 58 mg 10 x 10's (in Aluminum Strips)	Controlled Release Tablets of Sodium Valproate and Valproic Acid. White to off white, round, biconvex, plain film-coated tablet. Each tablet contains: Sodium Valproate BP 133.5 mg, Valproic acid USP 58 mg (Both together correspond to Sodium Valproate 200 mg in a Continus™ controlled-release system)	26/04/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AG01	Valproic acid	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AG Fatty acid derivatives
Discover more medicines within N03AG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-5954, A4-5955